214 related articles for article (PubMed ID: 31669808)
1. Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: An observational study in 8052 patients.
Fautrel B; Belhassen M; Hudry C; Woronoff-Lemsi MC; Levy-Bachelot L; Van Ganse E; Tubach F
Joint Bone Spine; 2020 Mar; 87(2):137-139. PubMed ID: 31669808
[TBL] [Abstract][Full Text] [Related]
2. UltraSound evaluation in follow-up of urate-lowering therapy in gout phase 2 (USEFUL-2): Duration of flare prophylaxis.
Ebstein E; Forien M; Norkuviene E; Richette P; Mouterde G; Daien C; Ea HK; Brière C; Lioté F; Petraitis M; Bardin T; Ora J; Dieudé P; Ottaviani S
Joint Bone Spine; 2020 Dec; 87(6):647-651. PubMed ID: 32979555
[TBL] [Abstract][Full Text] [Related]
3. Ultrasound evaluation in follow-up of urate-lowering therapy in gout: the USEFUL study.
Ebstein E; Forien M; Norkuviene E; Richette P; Mouterde G; Daien C; Ea HK; Brière C; Lioté F; Petraitis M; Bardin T; Ora J; Dieudé P; Ottaviani S
Rheumatology (Oxford); 2019 Mar; 58(3):410-417. PubMed ID: 30285127
[TBL] [Abstract][Full Text] [Related]
4. The value of musculoskeletal ultrasound in predicting gout flares in index joints: A prospective cohort study of people with gout starting urate-lowering therapy.
Han L; Li R; Dalbeth N; Liu M; Yu Q; Jiang C; Ning C; Liu Z; He Y; Li M; Xue X; Jia F; Jia Z; Sun W; Zhang H; Lu J; Wang C; Li C
Semin Arthritis Rheum; 2024 Aug; 67():152418. PubMed ID: 38422901
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare.
Janssen CA; Oude Voshaar MAH; Ten Klooster PM; Vonkeman HE; van de Laar MAFJ
Clin Rheumatol; 2019 Aug; 38(8):2233-2239. PubMed ID: 31030363
[TBL] [Abstract][Full Text] [Related]
6. Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares.
Choi HJ; Lee CH; Lee JH; Yoon BY; Kim HA; Suh CH; Choi ST; Song JS; Joo HY; Choi SJ; Lee JS; Shin KC; Baek HJ
Int J Rheum Dis; 2017 Apr; 20(4):497-503. PubMed ID: 25160939
[TBL] [Abstract][Full Text] [Related]
7. Comparative Risk of Gout Flares When Initiating or Escalating Various Urate-Lowering Therapy: A Systematic Review With Network Meta-Analysis.
Maher D; Reeve E; Hopkins A; Tan JM; Tantiongco M; Ailabouni N; Woodman R; Stamp L; Bursill D; Proudman S; Wiese M
Arthritis Care Res (Hoboken); 2024 Jun; 76(6):871-881. PubMed ID: 38303574
[TBL] [Abstract][Full Text] [Related]
8. Ultrasound Evaluation of Three Outcome Domains in the Follow-up of Urate-Lowering Therapy in Gout: An Observational Study.
Zhang W; Zhao D; Wu M; Chen W; Jin Z; Zhang H
Ultrasound Med Biol; 2021 Jun; 47(6):1495-1505. PubMed ID: 33785225
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study.
Hu S; Sun M; Li M; Xue X; Terkeltaub R; Wang C; Wang M; Lu J; Ran Z; Li H; Ji A; Sun W; Li X; He Y; Liu Z; Zhang H; Wang X; Ji X; Dalbeth N; Li C
Rheumatology (Oxford); 2023 Jul; 62(7):2435-2443. PubMed ID: 36409036
[TBL] [Abstract][Full Text] [Related]
10. Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study.
Uhlig T; Karoliussen LF; Sexton J; Kvien TK; Haavardsholm EA; Perez-Ruiz F; Hammer HB
Clin Rheumatol; 2022 Dec; 41(12):3817-3823. PubMed ID: 36316609
[TBL] [Abstract][Full Text] [Related]
11. Musculoskeletal Ultrasound in Monitoring the Efficacy of Gout: A Prospective Study Based on Tophus and Double Contour Sign.
Yuan H; Fan Y; Mou X; Qing Y; Yan X; Tang X; Yue W; Gu P; Yang Q; He Y
Balkan Med J; 2023 Mar; 40(2):104-110. PubMed ID: 36715053
[TBL] [Abstract][Full Text] [Related]
12. One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study.
Uhlig T; Karoliussen LF; Sexton J; Kvien TK; Haavardsholm EA; Perez-Ruiz F; Hammer HB
Arthritis Res Ther; 2022 Apr; 24(1):88. PubMed ID: 35443675
[TBL] [Abstract][Full Text] [Related]
13. Monosodium urate burden assessed with dual-energy computed tomography predicts the risk of flares in gout: a 12-month observational study : MSU burden and risk of gout flare.
Pascart T; Grandjean A; Capon B; Legrand J; Namane N; Ducoulombier V; Motte M; Vandecandelaere M; Luraschi H; Godart C; Houvenagel E; Norberciak L; Budzik JF
Arthritis Res Ther; 2018 Sep; 20(1):210. PubMed ID: 30223875
[TBL] [Abstract][Full Text] [Related]
14. Ultrasound sensitivity to changes in gout: a longitudinal study after two years of treatment.
Peiteado D; Villalba A; Martín-Mola E; Balsa A; De Miguel E
Clin Exp Rheumatol; 2017; 35(5):746-751. PubMed ID: 28281462
[TBL] [Abstract][Full Text] [Related]
15. Cohort study investigating gout flares and management in UK general practice.
Finnikin S; Mallen CD; Roddy E
BMC Prim Care; 2023 Nov; 24(1):246. PubMed ID: 37993770
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
[TBL] [Abstract][Full Text] [Related]
17. Seasonality of gout in Korea: a multicenter study.
Choi HJ; Lee CH; Lee JH; Yoon BY; Kim HA; Suh CH; Choi ST; Song JS; Joo H; Choi SJ; Lee JS; Shin K; Jun JB; Baek HJ
J Korean Med Sci; 2015 Mar; 30(3):240-4. PubMed ID: 25729244
[TBL] [Abstract][Full Text] [Related]
18. Two-year reduction of dual-energy CT urate depositions during a treat-to-target strategy in gout in the NOR-Gout longitudinal study.
Uhlig T; Eskild T; Karoliussen LF; Sexton J; Kvien TK; Haavardsholm EA; Dalbeth N; Hammer HB
Rheumatology (Oxford); 2022 Apr; 61(SI):SI81-SI85. PubMed ID: 34247224
[TBL] [Abstract][Full Text] [Related]
19. The Role of Ultrasound in Evaluating the Effect of Urate-lowering Drugs in Gout Patients.
El-Mallah R; Ibrahim RA; El Attar EA
Curr Rheumatol Rev; 2022; 18(4):338-345. PubMed ID: 36268549
[TBL] [Abstract][Full Text] [Related]
20. The GOUT-36 prediction rule for inpatient gout flare in people with comorbid gout: derivation and external validation.
Jatuworapruk K; Grainger R; Dalbeth N; Lertnawapan R; Hanvivadhanakul P; Towiwat P; Shi L; Taylor WJ
Rheumatology (Oxford); 2022 Apr; 61(4):1658-1662. PubMed ID: 34297058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
